Market Tracker

12/02 5:16pm ET

Alkermes Plc (NASDAQ:ALKS)

56.25
Delayed Data
As of Dec 02
 +1.36 / +2.48%
Today’s Change
27.14
Today|||52-Week Range
80.71
-29.14%
Year-to-Date
US Prisons Experiment With Addiction Treatment for Inmates
Nov 29 / GuruFocus News - Paid Partner Content
Acorda Stops Post-Stroke Development Program on Ampyra
Nov 22 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close54.89
Today’s open54.87
Day’s range54.37 - 56.73
Volume892,820
Average volume (3 months)1,084,590
Market cap$8.5B
Dividend yield--
Data as of 4:00pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-623.81%
Earnings growth (this year)+34.92%
Earnings growth (next 5 years)+57.70%
Revenue growth (last year)+1.54%
P/E ratioNM
Price/Sales18.85
Price/Book6.45

Competitors

 Today’s
change
Today’s
% change
RDYDr.Reddy's Laborator...+0.21+0.46%
SGENSeattle Genetics Inc-0.01-0.01%
TSROTESARO Inc+2.60+1.99%
JAZZJazz Pharmaceuticals...+0.56+0.55%
Data as of 4:02pm ET, 12/02/2016

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)$0.03
Annual revenue (last year)$628.3M
Annual profit (last year)-$227.2M
Net profit margin-36.15%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
President
Shane M. Cooke
Corporate headquarters
Dublin, Dublin

Forecasts